MedTrace Logo

Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin

NCT07349459 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-01-16

No results posted yet for this study

Summary

This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.

Conditions

  • Melatonin
  • Breast Cancer Patients Diagnosed
  • Vitamin D Concentration
  • Doxorubicin

Interventions

DRUG

Group 1 (Doxorubicin group)

30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks.

DRUG

Group 2: Vitamin D group

patients with Vitamin D supplementation (1000 iu/day) plus traditional therapy for 12 weeks

DRUG

Group 3: melatonin group

patients with 10 mg of melatonin orally, once daily plus traditional therapy for 12 weeks

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2026-08-30
Completion
2026-08-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07349459 on ClinicalTrials.gov